Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Genprex, Inc. (GNPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.51000.0000 (0.00%)
At close: 04:00PM EDT
Advertisement

Genprex, Inc.

3300 Bee Cave Road
Suite 650-227
Austin, TX 78746
United States
877 774 4679
https://www.genprex.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees17

Key Executives

NameTitlePayExercisedYear Born
Mr. John Rodney VarnerCo-Founder, Pres, CEO, Sec. & Chairman750.94kN/A1957
Mr. Ryan M. Confer M.S.Chief Financial Officer522.53kN/A1982
Ms. Catherine M. VaczyExec. VP, Gen. Counsel & Chief Strategy Officer646.02kN/A1961
Dr. Hemant Kumar C.P.M., EMBA, Ph.D.Chief Manufacturing & Technology OfficerN/AN/A1963
Ms. Kalyn DabbsSr. Mang. of Communications & MarketingN/AN/AN/A
Mr. David M. SchlossSr. VP of HRN/AN/AN/A
Mr. Thomas C. Gallagher Esq.Sr. VP of Intellectual Property & LicensingN/AN/AN/A
Dr. William E. Gannon Jr.Member of Clinical Advisory Board & VP of Regulatory AffairsN/AN/AN/A
Dr. Mark S. Berger M.D.Chief Medical OfficerN/AN/A1955
Mr. Greg Jancarik C.M.A., CPA, M.B.A.Corp. ControllerN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement